Trials / Terminated
TerminatedNCT04389450
Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Pluristem Ltd. · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial will examine if a new treatment of Mesenchymal-like Adherent stromal Cells (called PLX-PAD) can help patients intubated and mechanically ventilated due to COVID-19 to recover more quickly with less complications.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PLX-PAD | PLX-PAD, allogeneic ex vivo expanded placental mesenchymal-like adherent stromal cells |
| BIOLOGICAL | Placebo | Placebo solution for injection |
Timeline
- Start date
- 2020-10-01
- Primary completion
- 2021-05-17
- Completion
- 2023-06-07
- First posted
- 2020-05-15
- Last updated
- 2024-08-30
Locations
13 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04389450. Inclusion in this directory is not an endorsement.